Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Seasonal influenza in children: Prevention and treatment with antiviral drugs

Flor M Munoz, MD, MSc
Section Editors
George B Mallory, MD
Morven S Edwards, MD
Deputy Editor
Mary M Torchia, MD


Influenza is an acute respiratory illness caused by influenza A or B viruses, which occurs in outbreaks worldwide every year, mainly during the winter seasons in temperate climates.

Certain groups of children are at increased risk of acquiring severe or complicated illness from influenza (table 1). Among healthy children, influenza generally is an acute, self-limited, and uncomplicated disease [1-3]. However, it can be associated with severe morbidity and mortality. Influenza causes an appreciable disease burden (eg, school and work absence, increased frequency of outpatient medical visits), and children are important vectors for the spread of disease. (See "Seasonal influenza in children: Clinical features and diagnosis", section on 'Epidemiology'.)

Immunization is the most important public health measure for the prevention of influenza infection [4-6]. However, antiviral drugs also may be used for prevention in high-risk patients who have not been immunized or who may have a suboptimal response to vaccine, in patients in whom influenza vaccine is contraindicated, and for anyone who wants to reduce their risk of acquiring influenza in seasons when the vaccine is a poor match for circulating influenza.

Antiviral drugs are an important treatment option for patients who develop influenza infection despite immunization and those who are not immunized. Families of infants and children who are susceptible to severe disease from influenza should be reminded that these children may develop influenza infection despite immunization. If so, they should be seen by their health care provider as soon as possible after symptom onset because treatment is most beneficial when started early in the course of influenza.

The use of antiviral drugs in the prevention and treatment of influenza in children will be presented here. Influenza vaccination in children and the use of antiviral drugs in adults are discussed separately. (See "Seasonal influenza in children: Prevention with vaccines" and "Prevention of seasonal influenza with antiviral drugs in adults" and "Treatment of seasonal influenza in adults".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: May 2017. | This topic last updated: Jun 15, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Guidance on the use of zanamivir, oseltamivir and amantadine for the treatment of influenza. Technology Appraisal No. 58. National Institute for Clinical Excellence London, 2003. www.nice.org.uk (Accessed on September 07, 2008).
  2. Kumar S, Havens PL, Chusid MJ, et al. Clinical and epidemiologic characteristics of children hospitalized with 2009 pandemic H1N1 influenza A infection. Pediatr Infect Dis J 2010; 29:591.
  3. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med 2006; 355:31.
  4. Guidance on the use of oseltamivir and amantadine for the prophylaxis of influenza. Technology Appraisal No. 67. National Institute for Clinical Excellence London, 2003. www.nice.org.uk (Accessed on August 07, 2008).
  5. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines. MMWR Recomm Rep 2016; 65:1.
  6. COMMITTEE ON INFECTIOUS DISEASES. Recommendations for Prevention and Control of Influenza in Children, 2016-2017. Pediatrics 2016; 138.
  7. Centers for Disease Control and Prevention. Influenza antiviral medications: Summary for clinicians. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed on September 14, 2016).
  8. Centers for Disease Control and Prevention (CDC). Update: influenza activity --- United States, October 3-December 11, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1651.
  9. Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010; 59:901.
  10. Centers for Disease Control and Prevention (CDC). Update: influenza activity--United States, October 3, 2010-February 5, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:175.
  11. Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2011-12 season and composition of the 2012-13 influenza vaccine. MMWR Morb Mortal Wkly Rep 2012; 61:414.
  12. Centers for Disease Control and Prevention (CDC). Influenza activity--United States, 2012-13 season and composition of the 2013-14 influenza vaccine. MMWR Morb Mortal Wkly Rep 2013; 62:473.
  13. Centers for Disease Control and Prevention. Update: influenza activity--United States and worldwide, May 19-September 28, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:838.
  14. Epperson S, Blanton L, Kniss K, et al. Influenza activity - United States, 2013-14 season and composition of the 2014-15 influenza vaccines. MMWR Morb Mortal Wkly Rep 2014; 63:483.
  15. Russell K, Blanton L, Kniss K, et al. Update: Influenza Activity--United States, October 4, 2015-February 6, 2016. MMWR Morb Mortal Wkly Rep 2016; 65:146.
  16. Davlin SL, Blanton L, Kniss K, et al. Influenza Activity - United States, 2015-16 Season and Composition of the 2016-17 Influenza Vaccine. MMWR Morb Mortal Wkly Rep 2016; 65:567.
  17. Blanton L, Mustaquim D, Alabi N, et al. Update: Influenza Activity - United States, October 2, 2016-February 4, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:159.
  18. Couch RB. Prevention and treatment of influenza. N Engl J Med 2000; 343:1778.
  19. ClinicalTrials.gov. Safety, PK, and effectiveness of IV peramivir versus oseltamivir in pediatric subjects with uncomplicated influenza https://clinicaltrials.gov/ct2/show/NCT02369159 (Accessed on May 25, 2016).
  20. Biota reports top-line data from its phase 2 "IGLOO" trial of laninamivir octanoate. http://investors.biotapharma.com/releasedetail.cfm?ReleaseID=863626 (Accessed on August 20, 2014).
  21. Tamiflu (oseltamivir phosphate) prescribing information. www.gene.com/download/pdf/tamiflu_prescribing.pdf (Accessed on January 02, 2013).
  22. US Food and Drug Administration. MedWatch Safety Alert. Relenza (zanamivir) inhalation powder www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm186081.htm (Accessed on September 06, 2011).
  23. Centers for Disease Control and Prevention. Intravenous influenza antiviral medications and CDC considerations related to investigational use of intravenous zanamivir for 2013-2014i nfluenza season. www.cdc.gov/flu/professionals/antivirals/intravenous-antivirals.htm (Accessed on February 11, 2014).
  24. FDA news release. FDA approves Rapivab to treat flu infection. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm (Accessed on December 23, 2014).
  25. RAPIVAB (peramivir injection), for intravenous use. Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206426s003lbl.pdf (Accessed on August 20, 2016).
  26. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127.
  27. Strong M, Burrows J, Stedman E, Redgrave P. Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, United Kingdom. Euro Surveill 2010; 15:pii/19565.
  28. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis 2010; 51:887.
  29. Siedler K, Skopnik H. Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis. Pediatr Infect Dis J 2010; 29:495.
  30. Kimberlin DW, Shalabi M, Abzug MJ, et al. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J 2010; 29:195.
  31. Okamoto S, Kamiya I, Kishida K, et al. Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatr Infect Dis J 2005; 24:575.
  32. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.
  33. Relenza (zanamivir) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008.
  34. U.S. Food and Drug Administration. Tamiflu pediatric adverse events: Questions and answers www.fda.gov/cder/drug/infopage/tamiflu/QA20051117.htm (Accessed on September 06, 2011).
  35. U.S. Food and Drug Administration. 2008 Safety alerts for drugs, biologics, medical devices, and dietary supplements. Tamiflu (oseltamivir phosphate). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm095044.htm (Accessed on September 06, 2011).
  36. U.S. Food and Drug Administration. 2008 Safety alerts for drugs, biologics, medical devices, and dietary supplements. Relenza (zanamivir). http://www.fda.gov/Safety/MedWatch/Safetyinformation/SafetyAlertsforHumanMedicalProducts/ucm094982.htm (Accessed on September 06, 2011).
  37. Hoffman KB, Demakas A, Erdman CB, et al. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012. BMJ 2013; 347:f4656.
  38. Pollack A. Childhood deaths in Japan bring new look at flu drug. New York Times, November 18, 2005.
  39. Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health 2009; 21:79.
  40. Lindemann L, Jacobsen H, Schuhbauer D, et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite. Eur J Pharmacol 2010; 628:6.
  41. Hoffmann G, Funk C, Fowler S, et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother 2009; 53:4753.
  42. Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 2009; 63:596.
  43. Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008; 31:1097.
  44. Terada K, Kawai Y, Monju A, et al. Adolescent jump case in Japan associated with influenza but not oseltamivir. Pediatr Infect Dis J 2008; 27:88.
  45. Hara K, Tanabe T, Nakano R, et al. Clinical characteristics of children with abnormal behaviors associated with influenza infection. J Jpn Pediatr Soc 2007; 111:38.
  46. Wang YH, Huang YC, Chang LY, et al. Clinical characteristics of children with influenza A virus infection requiring hospitalization. J Microbiol Immunol Infect 2003; 36:111.
  47. Huang YC, Li WC, Tsao KC, et al. Influenza-associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir. Pediatr Infect Dis J 2009; 28:647.
  48. Tanabe T, Hara K, Nakajima M, et al. Oseltamivir treatment for children showing abnormal behavior during influenza virus infection. Brain Dev 2010; 32:440.
  49. CDC issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008-09 influenza season. http://emergency.cdc.gov/HAN/han00279.asp (Accessed on September 06, 2011).
  50. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987; 80:275.
  51. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003.
  52. Gilbert BE, Wilson SZ, Knight V, et al. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob Agents Chemother 1985; 27:309.
  53. Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med 2009; 361:1713.
  54. Centers for Disease Control and Prevention. Flu Activity and Surveillance. http://www.cdc.gov/flu/weekly/fluactivitysurv.htm (Accessed on January 21, 2015).
  55. Blanton L, Kniss K, Smith S, et al. Update: Influenza Activity--United States and Worldwide, May 24-September 5, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:1011.
  56. American Academy of Pediatrics. Influenza. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.476.
  57. Wang K, Shun-Shin M, Gill P, et al. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2012; 1:CD002744.
  58. Shinjoh M, Takano Y, Takahashi T, et al. Postexposure prophylaxis for influenza in pediatric wards oseltamivir or zanamivir after rapid antigen detection. Pediatr Infect Dis J 2012; 31:1119.
  59. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014; :CD008965.
  60. Crawford SA, Clover RD, Abell TD, et al. Rimantadine prophylaxis in children: a follow-up study. Pediatr Infect Dis J 1988; 7:379.
  61. Glezen WP. Modifying clinical practices to manage influenza in children effectively. Pediatr Infect Dis J 2008; 27:738.
  62. Clover RD, Crawford SA, Abell TD, et al. Effectiveness of rimantadine prophylaxis of children within families. Am J Dis Child 1986; 140:706.
  63. Jackson RJ, Cooper KL, Tappenden P, et al. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect 2011; 62:14.
  64. Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, September 29-December 7, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:1032.
  65. Kashiwagi S, Watanabe A, Ikematsu H, et al. Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza. Clin Infect Dis 2016; 63:330.
  66. Nakano T, Ishiwada N, Sumitani T, et al. Inhaled laninamivir octanoate as prophylaxis for infleunza in children. Pediatrics 2016; 138:e20160109.
  67. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2011-2012. Pediatrics 2011; 128:813.
  68. Tamiflu (oseltamivir) for oral suspension: potential medication errors. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183714.htm (Accessed on September 06, 2011).
  69. FDA Public Health Alert: Potential medication errors with Tamiflu for oral suspension. www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm183649.htm (Accessed on September 06, 2011).
  70. Yin HS, Parker RM, Sanders LM, et al. Liquid Medication Errors and Dosing Tools: A Randomized Controlled Experiment. Pediatrics 2016; 138.
  71. Khazeni N, Bravata DM, Holty JE, et al. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med 2009; 151:464.
  72. De Serres G. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) San Francisco, September 2009.
  73. Louie JK, Yang S, Samuel MC, et al. Neuraminidase inhibitors for critically ill children with influenza. Pediatrics 2013; 132:e1539.
  74. Smieja M. ACP Journal Club. Review: oseltamivir relieves symptoms but does not reduce hospitalizations in influenza. Ann Intern Med 2012; 157:JC3.
  75. Alves Galvao MG, Rocha Crispino Santos MA, Alves da Cunha AJ. Amantadine and rimantadine to prevent and treat influenza A in children and the elderly. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002745.pub3/abstract.
  76. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348:g2545.
  77. Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348:g2547.
  78. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123.
  79. Kawai N, Ikematsu H, Iwaki N, et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 2005; 40:1309.
  80. Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 2014; 14:109.
  81. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009; 124:170.
  82. Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ 2010; 341:c4779.
  83. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935.
  84. Lee EH, Wu C, Lee EU, et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York city. Clin Infect Dis 2010; 50:1498.
  85. Farias JA, Fernández A, Monteverde E, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med 2010; 36:1015.
  86. Domínguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302:1880.
  87. Creanga AA, Johnson TF, Graitcer SB, et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol 2010; 115:717.
  88. Louie JK, Acosta M, Jamieson DJ, et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010; 362:27.
  89. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:512.
  90. Falagas ME, Koletsi PK, Vouloumanou EK, et al. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65:1330.
  91. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395.
  92. Coffin SE, Leckerman K, Keren R, et al. Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza: a retrospective cohort study. Pediatr Infect Dis J 2011; 30:962.
  93. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667.
  94. Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53:277.
  95. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385:1729.
  96. Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J 2005; 24:931.
  97. Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008; 47:339.
  98. Li CC, Wang L, Eng HL, et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg Infect Dis 2010; 16:1265.
  99. Ng S, Cowling BJ, Fang VJ, et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis 2010; 50:707.
  100. Kimberlin DW, Acosta EP, Prichard MN, et al. Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. J Infect Dis 2013; 207:709.
  101. Acosta EP, Jester P, Gal P, et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis 2010; 202:563.
  102. McPherson C, Warner B, Hunstad DA, et al. Oseltamivir dosing in premature infants. J Infect Dis 2012; 206:847.
  103. Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10:18.
  104. WHO. Clinical management of human infection with avian influenza A (H5N1) virus http://www.who.int/influenza/resources/documents/clinical_management_h5n1_15_08_2007/en/index.html (Accessed on October 18, 2011).
  105. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013; 346:f3039.
  106. Valinotto LE, Diez RA, Barrero PR, et al. Emergence of intratreatment resistance to oseltamivir in pandemic influenza A H1N1 2009 virus. Antivir Ther 2010; 15:923.
  107. Suhaila M, Tang JW, Lee HK, et al. Mixtures of oseltamivir-sensitive and -resistant pandemic influenza A/H1N1/2009 viruses in immunocompromised hospitalized children. Pediatr Infect Dis J 2011; 30:625.
  108. Nguyen HT, Fry AM, Loveless PA, et al. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 2010; 51:983.
  109. Whitley RJ, Boucher CA, Lina B, et al. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis 2013; 56:1197.
  110. CDC Recommendations for the amount of time persons with influenza-like illness should be away from others www.cdc.gov/h1n1flu/guidance/exclusion.htm (Accessed on September 06, 2011).